# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Joseph Pantginis reiterates Esperion Therapeutics (NASDAQ:ESPR) with a Buy and maintains $16...
– NILEMDO (bempedoic acid), a First-In-Class, Oral Treatment and NUSTENDI (bempedoic Acid / Ezetimibe Fixed-Dose Combination) R...
HC Wainwright & Co. analyst Joseph Pantginis reiterates Esperion Therapeutics (NASDAQ:ESPR) with a Buy and maintains $16...
Esperion Therapeutics and Otsuka Pharmaceutical report Phase 3 trial results for bempedoic acid in Japan, achieving significant...
The trial demonstrated statistically significant outcomes on the primary endpoint for bempedoic acid and highlighted its potent...
HC Wainwright & Co. analyst Joseph Pantginis reiterates Esperion Therapeutics (NASDAQ:ESPR) with a Buy and maintains $16...
Needham analyst Serge Belanger reiterates Esperion Therapeutics (NASDAQ:ESPR) with a Buy and maintains $8 price target.